Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
|ClinicalTrials.gov Identifier: NCT00024076|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : October 30, 2015
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer Malignant Mesothelioma Metastatic Cancer Thymoma and Thymic Carcinoma||Procedure: radiofrequency ablation||Phase 2|
- Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
- Determine the efficacy of this treatment, in terms of local control, in these patients.
- Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.
OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.
Patients are followed at 1, 3, 6, and 12 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Radiofrequency Ablation of Pulmonary Malignancy|
|Study Start Date :||May 2000|
|Primary Completion Date :||December 2006|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00024076
|United States, California|
|Jonsson Comprehensive Cancer Center, UCLA|
|Los Angeles, California, United States, 90095-1781|
|Study Chair:||Robert D. Suh, MD||Jonsson Comprehensive Cancer Center|